<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00120081</url>
  </required_header>
  <id_info>
    <org_study_id>SVI-04-01</org_study_id>
    <nct_id>NCT00120081</nct_id>
  </id_info>
  <brief_title>Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection</brief_title>
  <official_title>Phase 1, Single-Center, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study to Compare the Safety, Tolerability, and Immunogenicity of Three Intramuscular Administrations of Na-ASP-2 Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this clinical trial is to determine the safety and tolerability of&#xD;
      the Na-ASP-2 Hookworm Vaccine in healthy subjects following the administration of 3&#xD;
      intramuscular (IM) injections of the vaccine over 16 weeks using 3 different doses. The&#xD;
      secondary objective is to make a preliminary evaluation of the immunogenicity of each of the&#xD;
      3 doses of the vaccine in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is an urgent need for new tools to control human hookworm infection and to reduce its&#xD;
      burden of disease in developing countries. This is especially true for children and women of&#xD;
      reproductive age who represent populations that are highly vulnerable to the effects of&#xD;
      hookworm disease. Up to 65,000 deaths annually have been attributed to human hookworm&#xD;
      infection. However, the mortality estimates of hookworm pale in comparison to global disease&#xD;
      burden estimates.&#xD;
&#xD;
      The primary approach to hookworm control worldwide has been the frequent and periodic use of&#xD;
      benzimidazole anthelminthics for school-age children. However, school-based anthelminthic&#xD;
      chemotherapy programs miss populations highly vulnerable to hookworm, including adolescent&#xD;
      and adult women. In addition, high rates of hookworm re-infection occur within 4-12 months&#xD;
      following anthelminthic chemotherapy, and there is evidence for diminished efficacy of&#xD;
      benzimidazoles with frequent and periodic use, possibly because of emerging drug resistance.&#xD;
      These concerns have prompted interest in developing alternative tools for hookworm control.&#xD;
      Vaccination to prevent high intensity hookworm infection would alleviate the public health&#xD;
      deficiencies of drug treatment alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of three different doses of the Na-ASP-2 hookworm vaccine in healthy volunteers</measure>
    <time_frame>For the duration of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the immunogenicity, both humoral and cellular, of the vaccine at specified time points following vaccination</measure>
    <time_frame>2, 8, 10, 16, 18, 24, and 48 weeks after the first injection</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Hookworm Infection</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mcg Na-ASP-2/Alhydrogel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mcg Na-ASP-2/Alhydrogel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mcg Na-ASP-2/Alhydrogel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Na-ASP-2/Alhydrogel Hookworm Vaccine</intervention_name>
    <description>The recombinant hookworm protein Na-ASP-2 formulated on aluminum hydroxide adjuvant (Alhydrogel), in one of three dose concentrations, compared to a saline placebo control.</description>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_label>Medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>Inactive saline placebo control</description>
    <arm_group_label>Saline placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults 18 to 45 years of age.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  History, physical exam, and laboratory tests indicating good general health obtained&#xD;
             prior to the first injection.&#xD;
&#xD;
          -  All females must have a negative pregnancy test (FDA-approved test for β human&#xD;
             chorionic gonadotropin [β-HCG]) on the day of the first injection.&#xD;
&#xD;
          -  Serologic tests for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg), and hepatitis C virus (HCV) are negative at screening.&#xD;
&#xD;
          -  All subjects must agree to use an acceptable method of birth control from the start of&#xD;
             screening until 2 weeks after the third injection. Acceptable methods for female&#xD;
             subjects include hormonal contraceptives, intrauterine device (IUD), diaphragm with&#xD;
             spermicide, condoms, abstinence, surgically sterile (hysterectomy), and surgically&#xD;
             sterile partner. Acceptable methods for male subjects include surgical sterilization,&#xD;
             condoms, partner who uses an acceptable method of birth control, and abstinence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of anaphylaxis or allergy to vaccine components or allergy to insect&#xD;
             stings, including bee stings.&#xD;
&#xD;
          -  A past or current history of hookworm infection.&#xD;
&#xD;
          -  BMI &lt; 18.0 or &gt; 30.0.&#xD;
&#xD;
          -  Recent (&lt; 72 hours) history of febrile illness at the time of vaccination (temperature&#xD;
             &gt; 99.6°F or equivalent).&#xD;
&#xD;
          -  Received any immune globulin or blood product 3 months prior to injection or scheduled&#xD;
             within 4 weeks thereafter.&#xD;
&#xD;
          -  Had vaccination with a live virus vaccine within 4 weeks before receipt of the vaccine&#xD;
             or scheduled within 4 weeks thereafter.&#xD;
&#xD;
          -  Had vaccination with a killed vaccine, or allergy treatment with antigen injections&#xD;
             within 14 days of initial study injection.&#xD;
&#xD;
          -  Received an investigational agent within 4 weeks of initial study injection.&#xD;
&#xD;
          -  Known or suspected impairment of immunologic function including, but not limited to&#xD;
             clinically significant liver disease, diabetes mellitus, moderate to severe kidney&#xD;
             impairment (creatinine &gt; 1.5), any history of malignancy (except squamous cell or&#xD;
             basal cell skin cancer), HIV infection or autoimmune diseases, or concomitant&#xD;
             immunosuppressive medication such as glucocorticosteroids.&#xD;
&#xD;
          -  A history of essential hypertension, gastrointestinal abnormalities such as peptic&#xD;
             ulcer disease, cardiac (ECG abnormalities), pulmonary, hepatic, renal, pancreatic, or&#xD;
             neurologic disease.&#xD;
&#xD;
          -  Taken prescription medications with the exception of subjects on a stable regimen (&gt;&#xD;
             30 days) of: (1) hormone replacement therapy, (2) use of nasal steroids, (3) topical&#xD;
             therapy, (4) certain classes of antidepressants (i.e., selective serotonin re-uptake&#xD;
             inhibitors), (5) oral contraceptives, (6) nonsteroidal anti-inflammatory agents, or&#xD;
             (7) antihistamines or decongestants for seasonal allergies taken as needed.&#xD;
&#xD;
          -  Contraindication to IM injection such as anti-coagulant therapy or thrombocytopenia.&#xD;
&#xD;
          -  Pregnant, nursing, or expecting to conceive during the study.&#xD;
&#xD;
          -  Any history of chronic alcohol or drug abuse or current treatment with any known&#xD;
             prescribed or over-the-counter supplements that may be hepatotoxins.&#xD;
&#xD;
          -  Any subject who, in the Investigator's opinion, will be unable to adhere to protocol&#xD;
             requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Simon, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George Washington University Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sabin.org</url>
    <description>Sponsor's Web page</description>
  </link>
  <results_reference>
    <citation>Bethony JM, Simon G, Diemert DJ, Parenti D, Desrosiers A, Schuck S, Fujiwara R, Santiago H, Hotez PJ. Randomized, placebo-controlled, double-blind trial of the Na-ASP-2 hookworm vaccine in unexposed adults. Vaccine. 2008 May 2;26(19):2408-17. doi: 10.1016/j.vaccine.2008.02.049. Epub 2008 Mar 11.</citation>
    <PMID>18396361</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>July 7, 2005</study_first_submitted>
  <study_first_submitted_qc>July 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2005</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Maria Elena Bottazzi PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Hookworm</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Human Hookworm Infection</keyword>
  <keyword>Na-ASP-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hookworm Infections</mesh_term>
    <mesh_term>Ancylostomiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

